Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

InterbrandHealth

- PMLiVE

Take-up for Agnitio’s pull marketing platform soars

Closed-loop marketing business sees 50 per cent increase in last two months from healthcare agencies

- PMLiVE

NICE backs BMS-Pfizer’s Eliquis in atrial fibrillation

Final draft guidance recommends the drug for common heart condition

- PMLiVE

EU nod for Novo Nordisk’s Tresiba and Ryzodeg

Reduced risk of hypoglycaemia may give insulin products edge ahead of Sanofi’s Lantus

- PMLiVE

How to future-proof your brand

Step up your branding expertise to ward off untimely competition and negate the passing of the years

- PMLiVE

Pfizer gets CHMP backing for leukaemia drug bosutinib

Provides option for patients resistant to tyrosine kinase inhibitors

- PMLiVE

IQWiG finds some value in Pfizer’s Inlyta

Cost effectiveness body decides cancer drug has benefits over Bayer's Nexavar

- PMLiVE

AstraZeneca removes R&D and commercial heads

Pascal Soriot's leadership shake-up will see Martin Mackay and Tony Zook leave

- PMLiVE

Pfizer enters ADHD market with Quillivant XR launch

Gained rights last November as part of NextWave acquisition

- PMLiVE

Novo Nordisk creates all-diabetes pro-cycling team

Team Novo Nordisk includes more than 100 cyclists, triathletes and runners with diabetes

Building brand strength – Part 2

The Iconic Brands series to help you create your brand's unique DNA

- PMLiVE

Pfizer acquires spinal muscular atrophy research programme

Gains rights to drug candidate RG3039 in deal with Repligen that could be worth up to $70m

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links